448 related articles for article (PubMed ID: 32175651)
1. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
[TBL] [Abstract][Full Text] [Related]
2. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
3. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
4. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
6. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
7. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
8. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
10. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
Luo C; Lei M; Zhang Y; Zhang Q; Li L; Lian J; Liu S; Wang L; Pi G; Zhang Y
J Cell Mol Med; 2020 Jan; 24(2):1233-1244. PubMed ID: 31779055
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and immunotherapeutic implications of bilirubin metabolism-associated genes in lung adenocarcinoma.
Ren K; Ling X; Chen L; Li Z; Huang T
J Cell Mol Med; 2024 May; 28(9):e18346. PubMed ID: 38693853
[TBL] [Abstract][Full Text] [Related]
12. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344
[TBL] [Abstract][Full Text] [Related]
14. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
15. Prognostic signature of lung adenocarcinoma based on stem cell-related genes.
Huang Z; Shi M; Zhou H; Wang J; Zhang HJ; Shi J-
Sci Rep; 2021 Jan; 11(1):1687. PubMed ID: 33462260
[TBL] [Abstract][Full Text] [Related]
16. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
[TBL] [Abstract][Full Text] [Related]
17. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.
Han L; Shi H; Luo Y; Sun W; Li S; Zhang N; Jiang X; Gong Y; Xie C
Cancer Med; 2020 Dec; 9(24):9581-9594. PubMed ID: 33098370
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
20. Significance of
Hou Y; Tan S; Wang G
Genet Test Mol Biomarkers; 2021 May; 25(5):346-354. PubMed ID: 33956533
[No Abstract] [Full Text] [Related]
[Next] [New Search]
